the federal government thinks it will possibly maintain manufacturing websites in France | EUROtoday
Get real time updates directly on you device, subscribe now.
“Mour commitment is that Doliprane continues to be produced in France,” declared the Minister of the Economy, Antoine Armand, this Sunday, October 13 in BFMTV. The pharmaceutical firm Sanofi lately introduced that it was in discussions with the American funding fund CD&R to promote its over-the-counter subsidiary, Opella, which notably manufactures Doliprane, the best-selling drug in France.
For its half, the federal government is satisfied of acquiring commitments to keep up industrial websites in France. “Producing Doliprane in France is our sovereign industrial and health strategy, and it must remain so,” defended the Minister of Health.
This Monday, Antoine Armand, accompanied by the Minister of Industry, Marc Ferracci, will go to the manufacturing web site in Lisieux (Calvados) to debate with workers and their representatives the ensures they want to see from producers.
“Commitments will be made”
It stays to be seen how far the manager can go. Can he block the transaction, as some ask? Although Antoine Armand “will ask for guarantees likely to reassure both employees and the French in the medium term”, he added that “nothing seems forbidden at first glance if this is not the case “.
ALSO READ Faced with drug shortages, the “great resourcefulness” of medical doctors and sufferersThe authorities has established two important circumstances to approve the sale of Doliprane to the CD&R funding fund. First, it’s essential that France is ready to proceed to obtain ample provides of this drug, along with making certain the upkeep of manufacturing jobs within the territory.
“I very sincerely think that commitments will be made, which will be very solid, both to maintain jobs and to maintain security of supply for the French,” stated Marc Ferracci, Minister of Industry, this Sunday. These commitments goal to reassure workers and the inhabitants relating to the potential sale of one of many essential French pharmaceutical producers.
https://www.lepoint.fr/economie/doliprane-le-gouvernement-pense-pouvoir-garder-des-sites-de-production-en-france-13-10-2024-2572645_28.php